Zealand Pharma A/S. 

Based in Copenhagen, Denmark, Zealand Pharma A/S operates as a biotechnology company dedicated to the entire lifecycle of peptide-based medicines – from their initial discovery and development through to their ultimate commercialization. Its therapeutic portfolio primarily targets gastrointestinal and metabolic disorders, alongside other specialized conditions where existing treatments are insufficient. Currently, Zealand Pharma offers lixisenatide, marketed as Adlyxin and Lyxumia. They also commercialize Dasiglucagon, available in a single-use syringe or autoinjector format, which addresses severe hypoglycemia, congenital hyperinsulinism, and hypoglycemia following bariatric surgery. Additionally, Dasiglucagon is part of a dual-hormone artificial pancreas system designed for automated diabetes management. Beyond its current offerings, the company maintains a robust development pipeline. Notably, Dasiglucagon is advancing through Phase III clinical trials specifically for congenital hyperinsulinism, building on its existing applications. Another key pipeline candidate is glepaglutide, a long-acting GLP-2 analog, also in Phase III trials for the management of short bowel syndrome. Zealand Pharma A/S has established strategic collaboration agreements with several prominent pharmaceutical and biotech partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc. Established in 1998, the company maintains its headquarters in Copenhagen, Denmark.